633-29-4

Usage

InChI:InChI=1/C20H28O4/c1-18-8-5-13(21)11-12(18)3-4-14-15(18)6-9-19(2)16(14)7-10-20(19,24)17(22)23/h11,14-16,24H,3-10H2,1-2H3,(H,22,23)/t14-,15+,16+,18+,19+,20?/m1/s1

Upstream product

• 6762-52-3 20-Hydroxy-21-oxo-pregnadien-<4.17(20)>-on-(3) 
• 77881-13-1 17β-cyano-17α-hydroxy-4-androsten-3-one 
• 67-56-1 methanol 
• 152-58-9 Cortexolone 
• 81481-39-2 17α-hydroxy-3-oxo-4-androstene-17-carboxylic acid amide 

Downstream Products

• 206351-46-4 3-[(3R,3aS,5aS,6R,9aS,9bS)-3-Hydroxy-3a,6-dimethyl-3-(4-nitro-3-trifluoromethyl-phenylcarbamoyl)-7-oxo-dodecahydro-cyclopenta[a]naphthalen-6-yl]-propionic acid 
• 206351-47-5 N-(3'-trifluoromethyl-4'-nitrophenyl)-17α-hydroxy-3-oxo-4-azaandrost-5-ene-17β-carboxamide 
• 206351-45-3 N-(3'-trifluoromethyl-4'-nitrophenyl)-17α-hydroxy-3-oxoandrost-4-ene-17β-carboxamide 

Relevant academic research and scientific papers

Etiprednol dicloacetate, a new soft glucocorticoid drug candidate. Development of chemistry

During development of chemistry of the soft drug candidate etiprednol dicloacetate (BNP-166) 1) optimization studies on the three-step chemical synthesis resulted in a process that could be scaled-up to the kg level, 2) the impurity profile was determined, 3) synthetic routes were developed for the preparation of the radiolabeled target compound, and 4) a series of hydroxylated metabolites was prepared.

Synthesis of N-substituted 3-oxo-17β -carboxamide-4-aza-5α-androstanes and the tautomerism of 3-oxo-4-aza-5-androstenes

An N-aryl-3-oxo-4-aza-5α -androst-1-ene-17β carboxamide and three N-aryl or alkyl substituted 17α -hydroxy-3-oxo-4-aza-5α -androstane-17β -carboxamides were synthesized as antiandrogen candidates from 3-oxoandrost-4-ene-17β - carboxylic acid and androst-4-ene-3,17-dione respectively. The chemo- and stereoselective reduction of 3-oxo-4-aza-5-ene intermediates with formic acid and their tautomerism in a solution of chloroform and methanol were described.

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.